Bronchiolitis obliterans
Drug research and approvals for bronchiolitis obliterans: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 95 studies of bronchiolitis obliterans are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 5 open orphan designations naming it.
- Recruiting worldwide: 95
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis…NCT07771855 · Phase 2 · Hopital Foch · starts Jun 24, 2026
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged…NCT07771439 · Phase 3 · Sanofi · starts Oct 12, 2026
- Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host DiseaseNCT07733141 · Not applicable · City of Hope Medical Center · starts Mar 1, 2027
- Forced Oscillatory Technique for Bronchiolitis Obliterans Syndrome After Allogeneic Bone Marrow TransplantationNCT07730931 · Not applicable · Hadassah Medical Organization · starts Aug 19, 2021
- Dry Dynamic Cupping vs Instrument-Assisted Soft Tissue Mobilization for Chronic Myofascial Low Back PainNCT07685340 · Not applicable · Ibadat International University, Islamabad · starts Jan 1, 2026
- Study of AHB-171 in Chronic Hepatitis B ParticipantsNCT07630727 · Phase 2 · Ausper Biopharma Co., Ltd. · starts Jun 24, 2026
- A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCTNCT07606703 · Phase 2 · WeiShi · starts Sep 1, 2025
- A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With…NCT07600788 · Phase 1 · Ausper Biopharma Co., Ltd. · starts Jul 9, 2026
- Dental Cleaning to Prevent Chronic Graft-Versus-Host DiseaseNCT07535008 · Not applicable · Fred Hutchinson Cancer Center · starts May 12, 2026
Phase 3 6
- CyclosporineCyclophilin A modulator
- Fluticasone propionateGlucocorticoid receptor agonist
- AzithromycinBacterial 70S ribosome inhibitor
- SalmeterolBeta-2 adrenergic receptor agonist
- TacrolimusFK506-binding protein 1A inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
Phase 2 9
- BudesonideGlucocorticoid receptor agonist
- FormoterolBeta-2 adrenergic receptor agonist
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- Bortezomib26S proteasome inhibitor
- Interferon gamma-1bInterferon gamma receptor agonist
- NintedanibPlatelet-derived growth factor receptor inhibitor
- Pirfenidone
- Lactose,
Phase 1 or earlier 2
- ItacitinibTyrosine-protein kinase JAK1 inhibitor
- XenonDiagnostic agent
How its trials ended
95 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 19 whose ending is known, 42% met their primary endpoint, 0% missed it and 58% stopped early.
- Completed, result not reported4446%
- Ongoing2324%
- Status unknown99%
- Met its primary endpoint88%
- Stopped: enrollment or feasibility55%
- Stopped: other or unclear33%
- Stopped: sponsor or business decision22%
- Stopped: lack of efficacy11%
| Dec 21, 2021 | SirolimusTreatment of Bronchiolitis Obliterans Syndrome | AI Therapeutics, Inc. | Designated |
| Aug 7, 2018 | Interleukin-1 receptor antagonist (IL-1Ra,…Treatment of Bronchiolitis Obliterans | Onspira Therapeutics, Inc., a wholly owned subsidiary of Sumitomo Pharma America, Inc. | Designated |
| Apr 10, 2017 | Recombinant human club cell proteinTreatment of bronchiolitis obliterans | Trove Therapeutics, Inc. | Designated |
| May 11, 2009 | Liposomal cyclosporineTreatment of bronchiolitis obliterans | Zambon S.p.A. | Designated |
| Jun 24, 2008 | Liposomal cyclosporine for inhalationPrevention of bronchiolitis obliterans. | Zambon S.p.A. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA